Prime Medicine, Inc. (PRME): R&D Expense
$160.64M
Year ended 2025-12-31
$146.20M
Trailing 12 months to 2026-06-30
+22.8%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $160.64M | +3.4% | 2026-03-03, From 2025-01-01 |
| 2024-12-31 | $155.29M | +5.0% | 2026-03-03, From 2024-01-01 |
| 2023-12-31 | $147.91M | +70.5% | 2025-02-28, From 2023-01-01 |
| 2022-12-31 | $86.72M | +22.9% | 2024-03-01, From 2022-01-01 |
| 2021-12-31 | $70.55M | n/m | 2023-03-09, From 2021-01-01 |
| 2020-12-31 | $2.98M | n/a | 2023-03-09, From 2020-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $160.64M | +3.4% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $39.75M | +23.7% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $100.0K | -39.0% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $116.64M | +42.1% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $116.68M | +30.6% |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $284.81M | -8.2% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $29.36M | +39.0% |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | $107.83M | -20.1% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $2.15M | +5.4% |
Compare PRME, OCGN, ZEOX, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗